The Haematological Malignancies Clinical Research Unit focuses on 3 main objectives:
Molecular research of haematological cancers: studying of cancer induced changes at the proteomic and genomic levels. We aim to: i) find new genomic and proteomics biomarkers for a better diagnosis of these haematological diseases; ii) detect new molecular alterations as predictors of response to a treatment, for example by studying minimal residual disease; and iii) study immune mechanisms of cancer control, with a special focus on NK cells.
In vitro & in vivo research: i) to establish the effects of new anticancer molecules in in vitro models of the disease; ii) to determine the mechanisms of resistance to anticancer drugs.
Clinical research: translate preclinical findings to the patients through a phase I clinical trials unit.
Spectrum and functional validation of PSMB5 mutations in multiple myeloma.(2018) Barrio S, Stühmer T, Da-Viá M, Barrio-Garcia C, Lehners N, Besse A, Cuenca I, Garitano-Trojaola A, Fink S, Leich E, Chatterjee M, Driessen C, Martinez-Lopez J, Rosenwald A, Beckmann R, Bargou RC, Braggio E, Stewart AK, Raab MS, Einsele H, Kortüm KM. Leukemia (in press).
Novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.(2018) Onecha E, Linares M, Rapado I, Ruiz-Heredia Y, Martinez-Sanchez P, Cedena T, Pratcorona M, Perez Oteyza J, Herrera P, Barragan E, Montesinos P, Garcia Vela JA, Magro E, Anguita E, Figuera A, Riaza R, Martinez-Barranco P, Sanchez-Vega B, Nomdedeu J, Gallardo M, Martinez-Lopez J, Ayala R Haematologica (in press).
Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing.(2018) Ruiz-Heredia Y, Sánchez-Vega B, Onecha E, Barrio S, Alonso R, Martínez-Ávila JC, Cuenca I, Agirre X, Braggio E, Hernández MT, Martínez R, Rosiñol L, Gutierrez N, Martin-Ramos M, Ocio EM, Echeveste MA, de Oteyza JP, Oriol A, Bargay J, Gironella M, Ayala R, Bladé J, Mateos MV, Kortum KM, Stewart K, García-Sanz R, Miguel JS, Lahuerta JJ, Martinez-Lopez J. Haematologica 103, e544-e548.
Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients.(2018) Macauda A, Castelli E, Buda G, Pelosini M, Butrym A, Watek M, Kruszewski M, Vangsted AJ, Rymko M, Jamroziak K, Abildgaard N, Haastrup EK, Mazur G, Ríos R, Jurczyszyn A, Zawirska D, Dudzinski M, Razny M, Dutka M, Tomczak W, Suska A, Druzd-Sitek A, Marques H, Petrini M, Markiewicz M, Martinez-Lopez J, Ebbesen LH, Iskierka-Jazdzewska E, Sainz J, Canzian F, Campa D. Br J Haematol 183, 375-384.
nherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients.(2018) Macauda A, Castelli E, Buda G, Pelosini M, Butrym A, Watek M, Kruszewski M, Vangsted AJ, Rymko M, Jamroziak K, Abildgaard N, Haastrup EK, Mazur G, Ríos R, Jurczyszyn A, Zawirska D, Dudzinski M, Razny M, Dutka M, Tomczak W, Suska A, Druzd-Sitek A, Marques H, Petrini M, Markiewicz M, Martinez-Lopez J, Ebbesen LH, Iskierka-Jazdzewska E, Sainz J, Canzian F, Campa D. Br J Haematol (in press).
Functional role and therapeutic targeting of p21-activated kinase 4 in multiple mieloma.(2017) Fulciniti M, Martinez-Lopez J, Senapedis W, Oliva S, Bandi RL, Amodio N, Xu Y, Szalat RL, Gulla A, Samur MK, Roccaro A, Linares M, Cea M, Baloglu E, Argueta C, Landesman Y, Shacham S, Liu S, Schenone M, Wu SL, Karger B, Prabhala R, Anderson KC, Munshi NC. Blood 129, 2233-2245.
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.(2017) Alvarez-Larrán A, Pérez-Encinas M, Ferrer-Marin F, Hernández-Boluda JC, Ramírez MJ, Martínez-López J, Magro E, Cruz Y, Mata MI, Aragües P, Fox ML, Cuevas B, Montesdeoca S, Hernández-Rivas JA, García-Gutiérrez V, Gómez-Casares MT, Steegmann JL, Durán MA, Gómez M, Kerguelen A, Bárez A, García MC, Boqué C, Raya JM, Martinez C, Albors M, Garcia F, Burgaleta C, Besses C. Haematologica 102, 103-109.
A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.(2017) Jiménez C, Jara-Acevedo M, Corchete LA, Castillo D, Ordóñez GR, Sarasquete ME, Puig N, Martínez-López J, Prieto-Conde MI, García-Álvarez M, Chillón MC, Balanzategui A, Alcoceba M, Oriol A, Rosiñol L, Palomera L, Teruel AI, Lahuerta JJ, Bladé J, Mateos MV, Orfão A, San Miguel JF, González M, Gutiérrez NC, García-Sanz R. J Mol Diagn 19, 99-106.
Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.(2015) Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, Dumontet C, Dudzi?ski M, Fejerman L, Greenberg A, Huntsman S, Jamroziak K, Jurczyszyn A, Kumar S, Atanackovic D, Glenn M, Cannon-Albright LA, Jones B, Lee A, Marques H, Martin T, Martinez-Lopez J, Rajkumar V, Sainz J, Juul Vangsted A, Watek M, Wolf J, Slager S, Camp NJ, Canzian F, Vachon C. Nat Communications 6, 7539-.
Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.(2015) Martínez-López J, Paiva B, López-Anglada L, Mateos MV, Cedena T, Vidríales MB, Sáez-Gómez MA, Contreras T, Oriol A, Rapado I, Teruel AI, Cordón L, Blanchard MJ, Bengoechea E, Palomera L, de Arriba F, Cueto-Felgueroso C, Orfao A, Bladé J, San Miguel JF, Lahuerta JJ; Spanish Multiple Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative Study Group. Blood 126, 858-862.
Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length.(2015) Campa D1, Martino A, Varkonyi J, Lesueur F, Jamroziak K, Landi S, Jurczyszyn A, Marques H, Andersen V, Jurado M, Brenner H, Petrini M, Vogel U, García-Sanz R, Buda G, Gemignani F, Ríos R, Vangsted AJ, Dumontet C, Martínez-López J, Moreno MJ, Stepien A, Watek M, Moreno V, Dieffenbach AK, Rossi AM, Butterbach K, Jacobsen SE, Goldschmidt H, Sainz J, Hillengass J, Orciuolo E, Dudzinski M, Weinhold N, Reis RM, Canzian F Int J Cancer 136, E351-E358.
Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium.(2015) Rios R, Lupiañez CB, Campa D, Martino A, Martínez-López J, Martínez-Bueno M, Varkonyi J, García-Sanz R, Jamroziak K, Dumontet C, Jerez-Cayuela A, W?tek M, Landi S, Rossi AM, Lesueur F, Reis RM, Moreno V, Marques H, Jurczyszyn A, Andersen V, Vogel U, Buda G, Orciuolo E, Jacobsen SE, Petrini M, Vangsted AJ, Gemignani F, Canzian F, Jurado M, Sainz J Endocr-Relat Cancer 22, 545-559.
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions.(2014) Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M New Engl J Med 370, 1101-1110.
RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia.(2014) Papaemmanuil E1, Rapado I2, Li Y1, Potter NE3, Wedge DC1, Tubio J1, Alexandrov LB1, Van Loo P4, Cooke SL1, Marshall J1, Martincorena I1, Hinton J1, Gundem G1, van Delft FW5, Nik-Zainal S1, Jones DR1, Ramakrishna M1, Titley I3, Stebbings L1, Leroy C1, Menzies A1, Gamble J1, Robinson B1, Mudie L1, Raine K1, O'Meara S1, Teague JW1, Butler AP1, Cazzaniga G6, Biondi A6, Zuna J7, Kempski H8, Muschen M9, Ford AM3, Stratton MR1, Greaves M10, Campbell PJ Nat Genet 46, 116-125.
Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database.(2014) Thompson BA, Spurdle AB, Plazzer JP, Greenblatt MS, Akagi K, Al-Mulla F, Bapat B, Bernstein I, Capellá G, den Dunnen JT, du Sart D, Fabre A, Farrell MP, Farrington SM, Frayling IM, Frebourg T, Goldgar DE, Heinen CD, Holinski-Feder E, Kohonen-Corish M, Robinson KL, Leung SY, Martins A, Moller P, Morak M, Nystrom M, Peltomaki P, Pineda M, Qi M, Ramesar R, Rasmussen LJ, Royer-Pokora B, Scott RJ, Sijmons R, Tavtigian SV, Tops CM, Weber T, Wijnen J, Woods MO, Macrae F, Genuardi M; InSiGHT Nat Genet 46, 107-115.
